Consensus Report From the Miami Liver Proton Therapy Conference
An international group of 22 liver cancer experts from 18 institutions met in Miami, Florida to discuss the optimal utilization of proton beam therapy (PBT) for primary and metastatic liver cancer. There was consensus that PBT may be preferred for liver cancer patients expected to have a suboptimal therapeutic ratio from XRT, but that PBT should not be preferred for all patients. Various clinical scenarios demonstrating appropriateness of PBT versus XRT were reviewed.
This article discusses its uses, effectiveness, and procedure.
The University of Kansas Health System signed an agreement with global medical technology company IBA to buy a proton therapy system, which is a highly specialized form of radiation treatment that will be offered through the University of Kansas Cancer Center. The $39 million-$45 million contract includes the price for a ProteusONE unit and a long-term operation and maintenance agreement. KU Health anticipates breaking ground on a new proton therapy center to house the treatment system later this…
Proton beam therapy is a rapidly developing tool in cancer treatment. This educational piece will outline the key physical, biological and clinical parameters that give a basic understanding of the radiobiology of proton therapy (Figure 1). In particular, it will focus on the important parameters of linear energy transfer (LET) and relative biological effectiveness (RBE).
Conclusion: The automated prior-plan adaptation method can successfully adapt for the large day-to-day variations observed in cervical cancer patients. PMID: 31271076 [PubMed - as supplied by publisher]
(University of Pennsylvania School of Medicine) Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients.
ConclusionsVMAT is now widely available, and high-quality VMAT plans that incorporate cardiac substructures into the optimization process can provide overall improvements in dose to OARs and, in particular, substantial sparing of critical cardiac structures. IMPT provides some incremental dosimetric improvements beyond cardiac-optimized VMAT, the clinical significance of which remains uncertain.
ConclusionRITI can be induced in patients with NSCLC through upregulated IgG and/or IgM. RITI response was not associated with proton versus photon therapy or with clinical outcomes in this small cohort and should be examined in a larger cohort in future studies.
This study was performed to determine the clinical and patient-reported outcomes for patients with PC treated with HFPT.
CONCLUSIONS: IMPT following IBR spared underlying organs and had low rates of acute toxicity. Reconstruction complications are more common in irradiated breasts, and reconstructive outcomes appear comparable with photon literature. Hypofractionation was associated with higher reconstruction failure rates. Further investigation of optimal dose-fractionation after IBR is needed. PMID: 31185327 [PubMed - as supplied by publisher]
PMID: 31166085 [PubMed - as supplied by publisher]